Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Duozhi ^a   Cai, Jieyun ^a   Cheng, Junjun ^b   Jing, Chenxu ^a,c   Yin, Junlin ^a   Jiang, Jiandong ^b   Peng, Zonggen ^b   Hao, Xiaojiang ^a  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^c YUNNAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMARYLLIDACEAE ALKALOID; ANTIVIRUS AGENT; CORE PROTEIN; HEAT SHOCK COGNATE PROTEIN 70; HSPA8 PROTEIN, HUMAN; KETONE; LYCORINE; PHENANTHRIDINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HOST PATHOGEN INTERACTION; HUMAN; HYDROGENATION; LIVER CELL; METABOLISM; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE; VIROLOGY; VIRUS REPLICATION;

AMARYLLIDACEAE ALKALOIDS; ANTIVIRAL AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG DESIGN; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HSC70 HEAT-SHOCK PROTEINS; HUMANS; HYDROGENATION; KETONES; PHENANTHRIDINES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL CORE PROTEINS; VIRUS REPLICATION;

EID: 84943242394     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14972     Document Type: Article

References (17)

1. Gordon, C. P., Keller, P. A. Control of hepatitis C: a medicinal chemistry perspective. J. Med. Chem. 48, 1-20 (2004).
2. Huang, Z., Murray, M. G., Secrist, J. A. Development of therapeutics for chronic HCV infection. Antiviral. Res. 71, 351-362 (2006).
3. Houghton, M., Abrignani, S. Prospects for a vaccine against the hepatitis C virus. Nature. 436, 961-966 (2005).
4. Leung, D., Abbenante, G., Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 43, 305-341 (2000).
5. Upasana, R., Saumitra, D. Interplay between NS3 protease and human La protein regulates translation-replication switch of hepatitis C virus. Sci. Rep. 1, 1, doi: 10.1038/srep00001 (2011).
6. Salah, E. D. R., Abdel, M. A. R., El-Halawany, A. M., Hattori, M., Abdel, S. E. HCV-NS3/4A protease inhibitory iridoid glucosides and dimeric foliamenthoic acid derivatives from anarrhinum orientale. J. Nat. Prod. 74, 943-948 (2011).
7. Salam, K. A. et al. Inhibition of hepatitis C virus NS3 helicase by manoalide. J. Nat. Prod. 75, 650-654 (2012).
8. Guan, L., Disney, M. D. Recent advances in developing small molecules targeting RNA. ACS Chem. Biol. 7, 73-86 (2011).
9. Czarniecki, M. Small molecule modulators of toll-like receptors. J. Med. Chem. 51, 6621-6626 (2008).
10. David, S. C. et al. Hepatitis C virus antigenic convergence. Sci. Rep. 2, 267, doi: 10.1038/srep00267 (2012).
11. Gabrielsen, B. et al. Antiviral (RNA) activity of selected amaryllidaceae isoquinoline constituents and synthesis of related substances. J. Nat. Prod. 55, 1569-1581 (1992).
12. Ieven, M. et al. Plant antiviral agents.3 Isolation of alkaloids from clivia miniata regel (amaryllidaceae). J. Nat. Prod. 45, 564-573 (1982).
13. Lamoral, T. D. et al. Lycorine, the main phenanthridine amaryllidaceae alkaloid, Exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. J. Med. Chem. 52, 6244-6256 (2009).
14. Antonio, E. et al. Biological evaluation of structurally diverse amaryllidaceae alkaloids and their synthetic derivatives: discovery ofnovel leads for anticancer drug design. Planta Med. 52, 501-507 (2009).
15. Jerald, N. J. et al. Cytotoxicity studies of lycorine alkaloids of the Amaryllidaceae. Nat. Prod. Commun. 9, 1193-1210 (2014).
16. Toriizuka, Y. et al. New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives. Bioorg. Med. Chem. 16, 10182-10189 (2008).
17. Lin, C. et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279, 17508-17514 (2004).